Skip to main content

Drug Interactions between meningococcal conjugate vaccine and ublituximab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

meningococcal conjugate vaccine ublituximab

Applies to: meningococcal conjugate vaccine and ublituximab

MONITOR: The administration of inactivated, killed, or otherwise noninfectious vaccines to patients receiving B-cell depletion therapy with ublituximab has not been studied but may be associated with diminished or suboptimal immunologic response. Ublituximab use causes a depletion of B-cells and can be expected to similarly increase the risk of a decreased or suboptimal immunologic vaccine response if immunization occurs before B-cells counts have recovered. Pharmacodynamic data has shown the median time to B-cell repletion following discontinuation of ublituximab is 70.3 weeks (range 0.1 to 75.1 weeks). For infants of mothers who have been exposed to ublituximab during pregnancy, there is a potential for depletion of B cells in their infants.

MANAGEMENT: Ublituximab therapy may interfere with the effectiveness of non-live vaccines. Immunization status should be assessed prior to initiating ublituximab and recommended immunizations with non- live vaccines should be completed whenever possible at least 2 weeks prior to ublituximab initiation. For infants of mothers exposed to ublituximab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted. Local vaccination guidelines and prescribing information for individual vaccines should be consulted for further guidance.

References

  1. (2022) "Product Information. Briumvi (ublituximab)." TG Therapeutics, Inc.

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.